Filing Flows › bioAffinity Technologies (BIAF) › Medical Director Fees revenue
bioAffinity Technologies (BIAF) Medical Director Fees revenue by quarter
bioAffinity Technologies' Medical Director Fees revenue was $17K in Q3 2026 (third quarter 2026), -2% from Q2 2026. Over the last 6 quarters it ranged from $17K (Q1 2025) to $18K (Q2 2026).
| Quarter | Medical Director Fees revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $17K | -2% | -0.4% |
| Q2 2026 | $18K | +0.5% | — |
| Q1 2026 | $17K | +2% | +5% |
| Q4 2025 | $17K | -1% | — |
| Q3 2025 | $17K | +4% | — |
| Q1 2025 | $17K | — | — |
Q3 2026 at a glance
bioAffinity Technologies, Q3 2026: revenue $1.1M (-26% year over year), operating margin -328.0%, net loss $5.3M, operating cash flow −$3.9M. The chart follows the revenue to costs, profit and cash.
Questions
What is bioAffinity Technologies' Medical Director Fees revenue?
bioAffinity Technologies' Medical Director Fees revenue was $17K in Q3 2026 (third quarter 2026), -2% from Q2 2026.
How has bioAffinity Technologies' Medical Director Fees revenue changed?
Over the last 6 quarters it ranged from $17K (Q1 2025) to $18K (Q2 2026).
Q3 2026 results → · How bioAffinity Technologies makes money →